Same peptide, two delivery routes. Where you want it to work determines how you take it.
Bottom line: This is not a which-is-better question, it is a where-is-the-problem question. Gut issues go oral. Tendons, ligaments, and systemic recovery go injectable. The oral form is uniquely stable in stomach acid (most peptides get destroyed), which makes oral BPC-157 a real option rather than a compromise. Some people run both routes simultaneously for different targets.
| BPC-157 Oral | Injectable | |
|---|---|---|
| Category | Oral capsule/liquid | Subcutaneous injection |
| Mechanism | Survives gastric acid (unusually stable for a peptide), acts locally on gut mucosa before partial systemic absorption | Bypasses GI tract entirely — direct absorption into bloodstream and surrounding tissue |
| Reported dose | 500–1500 mcg/day oral (higher dose needed due to ~10–20% bioavailability) | 250–500 mcg/day subcutaneous |
| Frequency | 1–2x daily, typically on empty stomach | 1x daily, injected near injury site when possible |
| Weight loss (trials) | Not a weight loss peptide | Not a weight loss peptide |
| Top side effect | Mild nausea, occasional GI discomfort (usually transient) | Injection site redness/irritation (mild, transient) |
| Evidence tier | Tier 2–3 — animal studies show oral stability, no human bioavailability comparison | Tier 2 — one human knee study (n=12), extensive animal data |
| Common vial size | Capsules (250–500 mcg) or oral liquid preparations | 5 mg vials |
| Approval status | Not FDA-approved in any form | Not FDA-approved in any form |
Oral BPC-157 makes the most sense when your target is the gut itself — leaky gut, IBD, gastric ulcers, NSAID damage, or GLP-1 nausea management. The peptide concentrates where it is most needed. Also the obvious choice if you genuinely cannot do injections.
Injectable BPC-157 is the call for musculoskeletal injuries — tendons, ligaments, joint inflammation — where you need systemic bioavailability and can inject near the injury site. Higher absorption means lower doses needed.
This is not a which-is-better question, it is a where-is-the-problem question. Gut issues go oral. Tendons, ligaments, and systemic recovery go injectable. The oral form is uniquely stable in stomach acid (most peptides get destroyed), which makes oral BPC-157 a real option rather than a compromise. Some people run both routes simultaneously for different targets.
← Browse all peptides | All comparisons →
vialprep research · Sources: PubMed, FDA, peer-reviewed trials · How we verify